Clinical efficacy of low-dose decitabine and homoharringtonine combined with CAG regimen in treatment of acute myeloid leukemia
10.3760/cma.j.issn.1009-9921.2019.08.006
- VernacularTitle:低剂量地西他滨、高三尖杉酯碱联合CAG方案治疗急性髓系白血病的临床效果
- Author:
Lin LIU
1
;
Xiaoli HUANG
;
Sanbin WANG
;
Le LUO
;
Zhongtao YUAN
Author Information
1. 解放军联勤保障部队第九二○医院血液科
- Keywords:
Leukemia,myeloid,acute;
Drug therapy,combination;
Decitabine;
Homoharringtonine;
CAG regimen
- From:
Journal of Leukemia & Lymphoma
2019;28(8):479-484
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of low-dose decitabine and homoharringtonine combined with CAG regimen (cytarabine, aclarubicin and recombinant human granulocyte colony-stimulating factor) (DHCAG regimen) in treatment of acute myeloid leukemia (AML). Methods Nineteen patients who were treated with DHCAG regimen in the 920th Hospital of Joint Logistics Support Force from July 2017 to June 2018 were retrospectively analyzed. Among them, 13 cases were newly diagnosed, 6 cases were ineffective or relapsed; 2 cases were elderly (≥60 years old); 15 cases had pulmonary infection before chemotherapy, and 4 cases had no lesions in the lungs when admitted to hospital. The remission rate and chemotherapy-related adverse reactions were analyzed. Results After 19 patients received one course of DHCAG regimen, 16 patients had complete remission, 1 patient had partial remission, 2 patients had no remission, and the overall response rate was 89.5% (17/19). Four patients with undetected lung disease before chemotherapy had no infection in the lungs after treatment. Among 15 patients with pulmonary infection before treatment, 1 patient died of pulmonary infection progress, the remaining 14 cases were grade 1-2 infection. 7 cases had bleeding, and 3 cases had nausea and vomiting, all of which were grade 1-2. Conclusion The remission rate of DHCAG regimen in treatment of AML is high, and its adverse reactions are tolerable.
